PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection

...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Jeffrey Silber ,Paul Feuerstadt ,Nasdaq ,Puretech Health ,Development Authority ,Twitter ,Biomedical Advanced Research ,Us Department Of Health ,Drug Administration ,Yale University School Of Medicine ,Administration For Strategic Preparedness ,Human Services ,Founded Entity ,Vedanta Biosciences ,Biologics License Application ,Biosciences Enrolls First Patient ,Pivotal Phase ,Chief Medical Officer ,Yale University School ,Orphan Drug Designation ,Fast Track Designation ,Strategic Preparedness ,Founded Entities ,Private Securities Litigation Reform Act ,Annual Report ,